Diabetes
BENTLEY ANNOUNCES APPROVAL AND EXPANSION OF ITS NASULIN PHASE II STUDIES IN INDIA
Published in Diabetes Week, March 5th, 2007
Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that it has received approval from the Drug Controller General of India (DCGI) to proceed with a Phase II clinical evaluation of its Nasulin(tm) in Type II diabetic patients. Nasulin(tm) is the Company's intranasal insulin product utilizing its proprietary CPE-215(R) delivery technology. This approval follows the completion of its pharmacokinetic clinical studies of Nasulin(tm) studies in India. This twelve week Phase II study will be initiated in March and expected to be completed before the end of 2007.
John Sedor, President of Bentley commented, "This expansion marks an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2007-03-05)
More Articles from Diabetes Week
- Anemia
Generic Biotech Medicines Could Save Plan Sponsors and Patients $71 Billion - Diabetes
"African Gene" Found - Diabetes
American Diabetes Association Collaborates with Pri-Med in Texas - Diabetes
BioSyntech announces start of patient recruitment into BST-DermOnTM pivotal clinical trial - Diabetes
Heritage Valley Physicians Receive Diabetes Recognition - Diabetes
Lilly Introduces World's First Digital Insulin Pen With Memory - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
